Only slight impact of predicted replicative capacity for therapy response prediction

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Weisser, Hendrik ^a   Altmann, André ^a   Sierra, Saleta ^b   Incardona, Francesca ^c   Struck, Daniel ^d   Sönnerborg, Anders ^e   Kaiser, Rolf ^b   Zazzi, Maurizio ^f   Tschochner, Monika ^g   Walter, Hauke ^g   Lengauer, Thomas ^a  

^a MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Informa Srl   (Italy)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF SIENA   (Italy)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AMINO ACID SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CORRELATION COEFFICIENT; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; LINEAR REGRESSION ANALYSIS; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; STUDENT T TEST; SUPPORT VECTOR MACHINE; TREATMENT RESPONSE; VIRUS LOAD; WILD TYPE; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; FACTUAL DATABASE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DATABASES, FACTUAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; MUTATION; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 77949344337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009044     Document Type: Article

References (32)

1. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, et al. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 2: 303-308.
2. Clercq ED (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33: 307-320.
3. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094.
4. Tisdale M, Kemp SD, Parry NR, Larder BA (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 90: 5653-5656.
5. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 338: 853-860.
6. Oette M, Kaiser R, Däumer M, Petch R, Fätkenheuer G, et al. (2006) Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41: 573-581.
7. Sagir A, Oette M, Kaiser R, Däumer M, Fätkenheuer G, et al. (2007) Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 60: 843-848.
8. Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, et al. (1999) Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol 13: 71-80.
9. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, et al. (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44: 920-928.
10. Hertogs K, de Béthune MP, Miller V, Ivens T, Schel P, et al. (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42: 269-276.
11. Laethem KV, Luca AD, Antinori A, Cingolani A, Perna CF, et al. (2002) A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 7: 123-129.
12. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, et al. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31: 298-303.
13. Beerenwinkel N, Däumer M, Oette M, Korn K, Hoffmann D, et al. (2003) Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 31: 3850-3855.
14. Vermeiren H, Craenenbroeck EV, Alen P, Bacheler L, Picchio G, et al. (2007) Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 145: 47-55.
15. Larder B, Wang D, Revell A, Montaner J, Harrigan R, et al. (2007) The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther 12: 15-24.
16. Altmann A, Rosen-Zvi M, Prosperi M, Aharoni E, Neuvirth H, et al. (2008) Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy. PLoS One 3: e3470.
17. Balduin M, Sierra S, Däumer MP, Rockstroh JK, Oette M, et al. (2005) Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. J Clin Virol 34: 277-287.
18. Nijhuis M, van Maarseveen NM, Boucher CAB (2009) Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb Exp Pharmacol. pp 299-320.
19. Quiñones-Mateu ME, Arts EJ (2002) Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat 5: 224-233.
20. Dykes C, Demeter LM (2007) Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev 20: 550-578.
21. Perrin L, Telenti A (1998) HIV treatment failure: testing for HIV resistance in clinical practice. Science 280: 1871-1873.
22. Grant P, Taylor J, Cain P, Short W, Gallant J, et al. (2009) Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. Clin Infect Dis 48: 680-682.
23. Birkner MD, Sinisi SE, van der Laan MJ (2005) Multiple testing and data adaptive regression: an application to HIV-1 sequence data. Stat Appl Genet Mol Biol 4: Article8.
24. Segal MR, Barbour JD, Grant RM (2004) Relating HIV-1 sequence variation to replication capacity via trees and forests. Stat Appl Genet Mol Biol 3: Article2; discussion article 7, article 9.
25. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, et al. (2001) Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344: 472-480.
26. R Development Core Team (2007) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available: http://www.R-project.org.
27. Dimitriadou E, Hornik K, Leisch F, Meyer D, Weingessel A (2007) e1071: Misc Functions of the Department of Statistics (e1071), TU Wien. R package version 1.5-17.
28. Peres Y, Bergroth T, Denholm-Price J, Incardona F, Kaiser R, et al. (2007) EuResist: Integrating and exchanging European HIV data. Eur J Med Res. pp 11-12.
29. Altmann A, Beerenwinkel N, Sing T, Savenkov I, Däumer M, et al. (2007) Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antivir Ther 12: 169-178.
30. De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, et al. (2003) Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 187: 1934-1943.
31. Shafer RW, Schapiro JM (2008) HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10: 67-84.
32. De Luca A, Weidler J, Di Giambenedetto S, Coakley E, Cingolani A, et al. (2007) Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. J Acquir Immune Defic Syndr 45: 411-417.